エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934.
Date of Report: February 5, 2025
(Date of earliest event reported)
Oragenics, Inc.
(Exact name of registrant as specified in its charter)
| FL | 001-32188 | 59-3410522 | ||
|
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
|
1990 Main Street Suite 750 Sarasota, FL |
34236 | |
| (Address of principal executive offices) | (Zip Code) |
813-286-7900
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock | OGEN | NYSE American |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 8.01. OTHER INFORMATION.
On February 5, 2025, Oragenics, Inc. (the “Company”) issued a press release announcing that the Company’s Chief Medical Officer, James P. Kelly, MA, MD, FAAN, FANA, will be a featured panelist at the 12th Annual Brain Health Summit, held on February 8, 2025, in conjunction with this year’s Super Bowl celebrations in New Orleans. A copy of the Press Release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release Dated, February 5, 2025. | |
| 104 | Cover page Interactive Data File (embedded in the cover page formatted in Inline XBRL) |
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 5th day of February 2025.
|
ORAGENICS, INC. |
||
| (Registrant) | ||
| BY: | /s/ Janet Huffman | |
|
Janet Huffman |
||
| Chief Financial Officer | ||
Exhibit 99.1
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Participate in the 12th Annual Brain Health Summit at the Leigh Steinberg Super Bowl Party 2025
SARASOTA, Fla., Feb. 5, 2025 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced that its Chief Medical Officer, James P. Kelly, MA, MD, FAAN, FANA, will be a featured panelist at the 12th Annual Brain Health Summit, held in conjunction with this year’s Super Bowl celebrations in New Orleans on February 8, 2025. The event will focus on advancing awareness, prevention, and care for athletic concussions and exploring innovative approaches to traumatic brain injury (TBI) treatment.
Dr. Kelly, a leading expert in neurology and concussion care, joins an esteemed lineup of thought leaders to discuss the long-term impact of TBIs, groundbreaking advances in treatment, and strategies for prevention. His expertise aligns with the summit’s mission to educate and inspire action in tackling the ongoing challenges posed by brain injuries in athletics.
“It’s an honor to contribute to this milestone event, which brings critical attention to the prevention and treatment of traumatic brain injuries,” said Dr. Kelly. “At Oragenics, we are at the forefront of innovation with ONP-002, our intranasal neurosteroid, designed to address the unmet needs of concussion treatment. Events like this summit are vital for fostering collaboration and exploring new approaches, such as leveraging neuroplasticity and advanced delivery systems, to transform how we care for athletes and others affected by TBIs.”
Now in its 12th year, the Brain Health Summit has become a cornerstone event for advancing the understanding and treatment of brain injuries in athletes. Hosted by legendary sports agent Leigh Steinberg, a long-time advocate for player safety and concussion awareness, the summit brings together top medical experts, former professional athletes, and industry leaders to drive meaningful change in brain health. This year’s event will once again feature Dr. Nicole Roberts as the moderator, who is the founder and President of Health & Human Rights Strategies and an expert in health innovation, technology, and brain health, particularly as it impacts vulnerable populations. Held alongside the excitement of the Super Bowl, the summit combines the sports community’s passion with a commitment to improving the lives of those affected by TBIs.
Investor Contact
Rich Cockrell
404.736.3838
ogen@cg.capital
About Oragenics, Inc.
Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, circumstances should change, except as otherwise required by law.